184 related articles for article (PubMed ID: 38363315)
1. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics.
Zheng S; Yang Z; Du G; Zhang Y; Jiang C; Xu T; Li B; Wang D; Qiu Y; Lin D; Zhang X; Shen J
Eur Radiol; 2024 Feb; ():. PubMed ID: 38363315
[TBL] [Abstract][Full Text] [Related]
2. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer.
Bian X; Du S; Yue Z; Gao S; Zhao R; Huang G; Guo L; Peng C; Zhang L
J Magn Reson Imaging; 2023 Nov; 58(5):1603-1614. PubMed ID: 36763035
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER+/HER2- Breast Cancer Quantified With 21-Gene Recurrence Score.
Chen Y; Tang W; Liu W; Li R; Wang Q; Shen X; Gong J; Gu Y; Peng W
J Magn Reson Imaging; 2023 Aug; 58(2):444-453. PubMed ID: 36440706
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
Peng Y; Zhang X; Qiu Y; Li B; Yang Z; Huang J; Lin J; Zheng C; Hu L; Shen J
AJR Am J Roentgenol; 2024 Apr; 222(4):e2330603. PubMed ID: 38265001
[No Abstract] [Full Text] [Related]
5. [Preoperative prediction of HER-2 expression status in breast cancer based on MRI radiomics model].
Zhang Y; Huang H; Yin L; Wang ZX; Lu SY; Wang XX; Xiang LL; Zhang Q; Zhang JL; Shan XH
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):428-437. PubMed ID: 38742356
[No Abstract] [Full Text] [Related]
6. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models.
Mao C; Hu L; Jiang W; Qiu Y; Yang Z; Liu Y; Wang M; Wang D; Su Y; Lin J; Yan X; Cai Z; Zhang X; Shen J
Eur Radiol; 2024 Apr; 34(4):2546-2559. PubMed ID: 37672055
[TBL] [Abstract][Full Text] [Related]
7. Intra- and Peritumoral Based Radiomics for Assessment of Lymphovascular Invasion in Invasive Breast Cancer.
Jiang W; Meng R; Cheng Y; Wang H; Han T; Qu N; Yu T; Hou Y; Xu S
J Magn Reson Imaging; 2024 Feb; 59(2):613-625. PubMed ID: 37199241
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Dynamic Contrast-Enhanced MRI and Non-Mono-Exponential Model-Based Diffusion-Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics.
Zhang L; Zhou XX; Liu L; Liu AY; Zhao WJ; Zhang HX; Zhu YM; Kuai ZX
J Magn Reson Imaging; 2023 Nov; 58(5):1590-1602. PubMed ID: 36661350
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric MRI-based radiomics nomogram for predicting the hormone receptor status of HER2-positive breast cancer.
Sang L; Liu Z; Huang C; Xu J; Wang H
Clin Radiol; 2024 Jan; 79(1):60-66. PubMed ID: 37838543
[TBL] [Abstract][Full Text] [Related]
10. Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer.
Zhou J; Tan H; Li W; Liu Z; Wu Y; Bai Y; Fu F; Jia X; Feng A; Liu H; Wang M
Acad Radiol; 2021 Oct; 28(10):1352-1360. PubMed ID: 32709582
[TBL] [Abstract][Full Text] [Related]
11. Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors.
Wang H; Hu D; Yao H; Chen M; Li S; Chen H; Luo J; Feng Y; Guo Y
Eur Radiol; 2019 Nov; 29(11):6182-6190. PubMed ID: 31016445
[TBL] [Abstract][Full Text] [Related]
12. Radiomics analysis of intratumoral and different peritumoral regions from multiparametric MRI for evaluating HER2 status of breast cancer: A comparative study.
Zhou J; Yu X; Wu Q; Wu Y; Fu C; Wang Y; Hai M; Tan H; Wang M
Heliyon; 2024 Apr; 10(7):e28722. PubMed ID: 38623231
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer.
Huang Y; Chen W; Zhang X; He S; Shao N; Shi H; Lin Z; Wu X; Li T; Lin H; Lin Y
Front Bioeng Biotechnol; 2021; 9():662749. PubMed ID: 34295877
[No Abstract] [Full Text] [Related]
14. Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer.
Huang Y; Wei L; Hu Y; Shao N; Lin Y; He S; Shi H; Zhang X; Lin Y
Front Oncol; 2021; 11():706733. PubMed ID: 34490107
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers.
Ramtohul T; Djerroudi L; Lissavalid E; Nhy C; Redon L; Ikni L; Djelouah M; Journo G; Menet E; Cabel L; Malhaire C; Tardivon A
Radiology; 2023 Aug; 308(2):e222646. PubMed ID: 37526540
[TBL] [Abstract][Full Text] [Related]
16. Elaboration of Multiparametric MRI-Based Radiomics Signature for the Preoperative Quantitative Identification of the Histological Grade in Patients With Non-Small-Cell Lung Cancer.
Tang X; Bai G; Wang H; Guo F; Yin H
J Magn Reson Imaging; 2022 Aug; 56(2):579-589. PubMed ID: 35040525
[TBL] [Abstract][Full Text] [Related]
17. Development and external validation of a multiparametric MRI-based radiomics model for preoperative prediction of microsatellite instability status in rectal cancer: a retrospective multicenter study.
Li Z; Zhang J; Zhong Q; Feng Z; Shi Y; Xu L; Zhang R; Yu F; Lv B; Yang T; Huang C; Cui F; Chen F
Eur Radiol; 2023 Mar; 33(3):1835-1843. PubMed ID: 36282309
[TBL] [Abstract][Full Text] [Related]
18. Radiomics analysis based on multiparametric magnetic resonance imaging for differentiating early stage of cervical cancer.
Wu F; Zhang R; Li F; Qin X; Xing H; Lv H; Li L; Ai T
Front Med (Lausanne); 2024; 11():1336640. PubMed ID: 38371508
[TBL] [Abstract][Full Text] [Related]
19. Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase.
Tang WJ; Kong QC; Cheng ZX; Liang YS; Jin Z; Chen LX; Hu WK; Liang YY; Wei XH; Guo Y; Jiang XQ
Eur Radiol; 2022 Feb; 32(2):864-875. PubMed ID: 34430998
[TBL] [Abstract][Full Text] [Related]
20. Use of MRI Radiomics Models in Evaluating the Low HER2 Expression in Breast Cancer.
Li H; Hou Y; Xue LY; Fan WL; Gao BL; Yin XP
Curr Med Imaging; 2024 May; ():. PubMed ID: 38726785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
